1. 首页
  2. 细胞
  3. 正文

Olaparib_763113-22-0_Absin

产品信息
抗原名称
PARP2;PARP1
商品描述

Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an Autophagy and Mitophagy activator.

分子量
434.46
纯度

>98%

可溶性
DMSO :80 mg/mL (184.1 mM)
外观
White powder
In vitro(体外研究)
Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways.
In vivo(体内研究)
Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors.
背景
别名
奥拉帕尼
分子式
C24H23FN4O3
CAS号
763113-22-0
制备和贮存
保存方式
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

参考图片

文档下载: W 导出为Olaparib_763113-22-0_Absin.doc文档

本文来自投稿,不代表本人立场,如若转载,请注明出处:http://www.iamyjet.com/article/23613.html

(function(){ var src = (document.location.protocol == "http:") ? "http://js.passport.qihucdn.com/11.0.1.js?1d7dde81dc0903e04d3ac0b9599444f6":"https://jspassport.ssl.qhimg.com/11.0.1.js?1d7dde81dc0903e04d3ac0b9599444f6"; document.write('<\/mip-script>'); })(); (function(){ var bp = document.createElement('script'); var curProtocol = window.location.protocol.split(':')[0]; if (curProtocol === 'https') { bp.src = 'https://zz.bdstatic.com/linksubmit/push.js'; } else { bp.src = 'http://push.zhanzhang.baidu.com/push.js'; } var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(bp, s); })();